Combination of
BupivacaineLocal anesthetic
MeloxicamNonsteroidal anti-inflammatory drug (NSAID)
Clinical data
Trade namesZynrelef
Other namesHTX-011
License data
Routes of
Intralesional, infiltration
ATC code
Legal status
Legal status
CAS Number

Bupivacaine/meloxicam, sold under the brand name Zynrelef, is a fixed-dose combination medication used to treat pain in small to medium-sized wounds after surgery.[1][2][3] It contains bupivacaine and meloxicam.[1][2]

The most common side effects of bupivacaine/meloxicam are dizziness, constipation, vomiting, and headache.[1][2]

It was approved for medical use in the European Union in September 2020,[2] and in the United States in May 2021.[1][4]

Medical uses

In the European Union, the combination bupivacaine/meloxicam is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults.[2]

In the United States it is indicated for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty in adults.[1][4]


  1. ^ a b c d e f "Zynrelef- bupivacaine and meloxicam solution". DailyMed. Retrieved 8 January 2022.
  2. ^ a b c d e f "Zynrelef EPAR". European Medicines Agency (EMA). 22 July 2020. Retrieved 6 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. ^ Blair HA (July 2021). "Bupivacaine/Meloxicam Prolonged Release: A Review in Postoperative Pain". Drugs. 81 (10): 1203–1211. doi:10.1007/s40265-021-01551-9. PMID 34228280.
  4. ^ a b "Heron Therapeutics Announces U.S. FDA Approval of Zynrelef (HTX-011) for the Management of Postoperative Pain for up to 72 Hours" (Press release). Heron Therapeutics. 13 May 2021. Retrieved 14 May 2021 – via PR Newswire.